BioLife Solutions (BLFS) Expected to Release Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is anticipated to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect BioLife Solutions to post earnings of $0.0271 per share and revenue of $27.7960 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $27.50 million for the quarter, compared to analysts’ expectations of $25.66 million. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS opened at $32.15 on Tuesday. The company has a market capitalization of $1.57 billion, a P/E ratio of -401.82 and a beta of 1.94. The company’s 50-day moving average is $27.87 and its 200 day moving average is $23.81. BioLife Solutions has a fifty-two week low of $17.86 and a fifty-two week high of $33.14.

Analyst Ratings Changes

Several brokerages have commented on BLFS. TD Cowen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $33.00 to $31.00 in a research report on Wednesday, July 22nd. Stephens restated an “equal weight” rating and set a $31.00 price target (down from $32.00) on shares of BioLife Solutions in a research note on Monday, July 27th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 28th. Maxim Group downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Finally, Craig Hallum lowered BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price objective for the company. in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $31.38.

Insider Buying and Selling

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $23.70, for a total value of $15,405,000.00. Following the completion of the transaction, the insider directly owned 4,757,165 shares in the company, valued at approximately $112,744,810.50. The trade was a 12.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 1,200,000 shares of company stock valued at $28,125,000. 2.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioLife Solutions

A number of large investors have recently made changes to their positions in BLFS. Global Retirement Partners LLC purchased a new position in BioLife Solutions during the 4th quarter valued at about $30,000. Kemnay Advisory Services Inc. purchased a new stake in shares of BioLife Solutions in the fourth quarter worth about $35,000. Quarry LP boosted its position in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 713 shares during the period. Strs Ohio bought a new position in shares of BioLife Solutions in the first quarter valued at approximately $153,000. Finally, Tower Research Capital LLC TRC grew its stake in BioLife Solutions by 547.9% during the second quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock valued at $154,000 after acquiring an additional 6,032 shares in the last quarter. 93.24% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.